Gastroenterology
Volume 139, Issue 2 , Pages 474-482 , August 2010

Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study

  • Jessica Liu

      Affiliations

    • Rollins School of Public Health, Emory University, Atlanta, Georgia
    • Genomics Research Center, Academia Sinica, Taipei, Taiwan
    • ,
  • Hwai–I. Yang

      Affiliations

    • Genomics Research Center, Academia Sinica, Taipei, Taiwan
    • ,
  • Mei–Hsuan Lee

      Affiliations

    • Genomics Research Center, Academia Sinica, Taipei, Taiwan
    • Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    • ,
  • Sheng–Nan Lu

      Affiliations

    • Department of Gastroenterology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan
    • ,
  • Chin–Lan Jen

      Affiliations

    • Genomics Research Center, Academia Sinica, Taipei, Taiwan
    • ,
  • Li–Yu Wang

      Affiliations

    • MacKay Medical College, Taipei, Taiwan
    • ,
  • San–Lin You

      Affiliations

    • Genomics Research Center, Academia Sinica, Taipei, Taiwan
    • ,
  • Uchenna H. Iloeje

      Affiliations

    • Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut
    • ,
  • Chien–Jen Chen

      Affiliations

    • Genomics Research Center, Academia Sinica, Taipei, Taiwan
    • Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    • Corresponding Author InformationReprint requests Address requests for reprints to: Chien-Jen Chen, ScD, Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan. fax: (886) 2-2787-8784
    • ,
  • REVEAL-HBV Study Group

Received 7 January 2010 ,Accepted 12 April 2010.

References 

  1. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000;15(Suppl):E3–E6
  2. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150:104–110
  3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  4. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15(Suppl):E25–E30
  5. World Health Organization. Hepatitis B Fact Sheet N204. Geneva, Switzerland: World Health Organization; 2008;
  6. Yuen MF, Lai CL. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000;15(Suppl):E20–E24
  7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–1241
  8. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745
  9. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592
  10. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797–816viii
  11. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–S308
  12. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26:142–152
  13. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;119:71.e9–71.e16
  14. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42:188–194
  15. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1089
  16. Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111–124
  17. Borgniet O, Parvaz P, Bouix C, et al. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol. 2009;81:1336–1342
  18. Carey WD. The prevalence and natural history of hepatitis B in the 21st century. Cleve Clin J Med. 2009;76(Suppl 3):S2–S5
  19. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101:297–303
  20. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139–145
  21. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187–1192
  22. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13:627–631
  23. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759–768
  24. Kim JH, Lee JH, Park SJ, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology. 2008;55:578–581
  25. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51:1531–1537
  26. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004;39:1694–1701
  27. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  28. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163
  29. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:S72–S84
  30. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660–1667
  31. Gish RG. Hepatitis B treatment: current best practices, avoiding resistance. Cleve Clin J Med. 2009;76(Suppl 3):S14–S19
  32. Yuen MF, Wong DK, Yuan HJ, et al. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol. 2004;42:4882–4884
  33. Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22:1081–1092
  34. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord. 1998;22:39–47
  35. Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26:5576–5582
  36. Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?. Int J Obes (Lond). 2007;31:871–875
  37. Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis. 2008;29:106–112

 Conflicts of interest These authors disclose the following: Dr Iloeje is an employee of and holds stock in Bristol-Myers Squibb Company. The remaining authors disclose no conflicts.

 Funding This study was supported by research grants from the Department of Health, Executive Yuan, Taipei, Taiwan; Academia Sinica, Taipei, Taiwan; National Health Research Institutes, Chunan, Taiwan; and the Bristol-Myers Squibb Company, Wallingford, CT, to conduct the laboratory tests for this study.The funding sources of this study had no role in the design or conduct of the study, nor did they have any role in the collection, management, analysis, and interpretation of the data as well as the preparation, review, or approval of the manuscript. All data handling and statistical analyses were performed by staff at the National Taiwan University and Academia Sinica. At no time did the funding sources have access to the data.

PII: S0016-5085(10)00656-6

doi: 10.1053/j.gastro.2010.04.048

Gastroenterology
Volume 139, Issue 2 , Pages 474-482 , August 2010

Article Tools

* Image Usage & Resolution